» Articles » PMID: 17163988

Duty, Desire or Indifference? A Qualitative Study of Patient Decisions About Recruitment to an Epilepsy Treatment Trial

Overview
Journal Trials
Publisher Biomed Central
Date 2006 Dec 14
PMID 17163988
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Epilepsy is a common neurological condition, in which drugs are the mainstay of treatment and drugs trials are commonplace. Understanding why patients might or might not opt to participate in epilepsy drug trials is therefore of some importance, particularly at a time of rapid drug development and testing; and the findings may also have wider applicability. This study examined the role of patient perceptions in the decision-making process about recruitment to an RCT (the SANAD Trial) that compared different antiepileptic drug treatments for the management of new-onset seizures and epilepsy.

Methods: In-depth interviews with 23 patients recruited from four study centres. All interviews were tape-recorded and transcribed; the transcripts were analysed thematically using a qualitative data analysis package.

Results: Of the nineteen informants who agreed to participate in SANAD, none agreed for purely altruistic reasons. The four informants who declined all did so for very specific reasons of self-interest. Informants' perceptions of the nature of the trial, of the drugs subject to trial, and of their own involvement were all highly influential in their decision-making. Informants either perceived the trial as potentially beneficial or unlikely to be harmful, and so agreed to participate; or as potentially harmful or unlikely to be beneficial and so declined to participate.

Conclusion: Most patients applied 'weak altruism', while maintaining self-interest. An emphasis on the safety and equivalence of treatments allowed some patients to be indifferent to the question of involvement. There was evidence that some participants were subject to 'therapeutic misconceptions'. The findings highlight the individual nature of trials but nonetheless raise some generic issues in relation to their design and conduct.

Citing Articles

The role of healthcare professionals' communication in trial participation decisions: a qualitative investigation of recruitment consultations and patient interviews across three RCTs.

Farrar N, Elliott D, Jepson M, Young B, Donovan J, Conefrey C Trials. 2024; 25(1):829.

PMID: 39695876 PMC: 11653767. DOI: 10.1186/s13063-024-08656-y.


Factors that impact on recruitment to vaccine trials in the context of a pandemic or epidemic: a qualitative evidence synthesis.

Meskell P, Biesty L, Dowling M, Roche K, Meehan E, Glenton C Cochrane Database Syst Rev. 2023; 9:MR000065.

PMID: 37655964 PMC: 10472890. DOI: 10.1002/14651858.MR000065.pub2.


Motivations and barriers for healthy participants to participate in herbal remedy clinical trial in Tanzania: A qualitative study based on the theory of planned behaviour.

Kassimu K, Milando F, Omolo J, Nyaulingo G, Mbarak H, Mohamed L PLoS One. 2022; 17(7):e0271828.

PMID: 35862395 PMC: 9302811. DOI: 10.1371/journal.pone.0271828.


Endometrial scratch to increase live birth rates in women undergoing first-time in vitro fertilisation: RCT and systematic review.

Metwally M, Chatters R, Pye C, Dimairo M, White D, Walters S Health Technol Assess. 2022; 26(10):1-212.

PMID: 35129113 PMC: 8859770. DOI: 10.3310/JNZT9406.


The lived experience of a novel disruptive therapy in a group of men and boys with haemophilia A with inhibitors: Emi & Me.

Fletcher S, Jenner K, Holland M, Khair K Health Expect. 2021; 25(1):443-454.

PMID: 34878209 PMC: 8849246. DOI: 10.1111/hex.13404.


References
1.
Bevan E, Chee L, McGhee S, McInnes G . Patients' attitudes to participation in clinical trials. Br J Clin Pharmacol. 1993; 35(2):204-7. PMC: 1381516. View

2.
Lidz C, Appelbaum P, Grisso T, Renaud M . Therapeutic misconception and the appreciation of risks in clinical trials. Soc Sci Med. 2004; 58(9):1689-97. DOI: 10.1016/S0277-9536(03)00338-1. View

3.
Schaeffer M, Krantz D, Wichman A, Masur H, Reed E, Vinicky J . The impact of disease severity on the informed consent process in clinical research. Am J Med. 1996; 100(3):261-8. DOI: 10.1016/S0002-9343(97)89483-1. View

4.
Ellis P . Attitudes towards and participation in randomised clinical trials in oncology: a review of the literature. Ann Oncol. 2000; 11(8):939-45. DOI: 10.1023/a:1008342222205. View

5.
Roberts F . Qualitative differences among cancer clinical trial explanations. Soc Sci Med. 2002; 55(11):1947-55. DOI: 10.1016/s0277-9536(01)00323-9. View